Twitter | Pretraživanje | |
BioPharmX
BioPharmX Corporation (NYSE American: ) is a specialty pharmaceutical company focused on optimizing drug delivery to benefit dermatology patients worldwide
243
Tweetovi
111
Pratim
1.743
Osobe koje vas prate
Tweetovi
BioPharmX 9. ruj
BioPharmX Reports Fiscal Second Quarter 2020 Financial Results and Provides Corporate Update
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 18. srp
Our new COO Mr. Bosacki previously served as President and CEO of Lautus Pharmaceuticals, a privately held pharmaceutical company focused on the and aesthetics markets. Learn more about his experience here:
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 17. srp
Our new COO Mr. Bosacki previously served as Senior Vice President and General Counsel under BioPharmX CEO, Dr. David S. Tierney, at Oceana Therapeutics
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 16. srp
BioPharmX today announces the appointment of Steven M. Bosacki, a 20 year pharmaceutical industry veteran, as its Chief Operating Officer
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 27. lip
BPX-04 was well-tolerated in a Phase 2b trial for moderate-to-severe papulopustular and the efficacy and safety profile observed supports advancement into Phase 3
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 26. lip
"We are pleased with the overwhelmingly positive outcome on both the primary and secondary efficacy measures as well as the confirmation of the safety and cutaneous tolerability of our minocycline gel formulation," commented CEO
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 25. lip
BPX-04 successfully met both the primary and secondary endpoints of the trial in demonstrating a statistically significant mean change in the number of facial inflammatory lesions and a two-grade improvement to clear or almost clear
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 25. lip
BioPharmX today announced positive results from its Phase 2b clinical trial of BPX-04, a novel topical gel formulation of fully solubilized minocycline for the treatment of moderate-to-severe papulopustular
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 13. lip
Approximately 40 to 50 million Americans suffer from vulgaris. We are developing BPX-01, a topical version of minocycline, for these patients. Learn more:
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 11. lip
BioPharmX Reports Fiscal First Quarter 2020 Financial Results
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 11. lip
is the most common skin condition that people experience. Most people develop acne to some degree during their lifetime. Understand the underlying causes of acne:
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 10. lip
In a Phase 2b study, BPX-01 demonstrated a 58% reduction in inflammatory acne lesions. Learn about our development of a novel, proprietary topical minocycline gel for vulgaris:
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 6. lip
BPX-04 was designed to deliver minocycline topically for patients looking to minimize systemic exposure to antibiotics. Learn more about the development program here:
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 5. lip
is a common skin disease that can cause redness, swelling, and acne-like breakouts. provides an overview:
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 3. lip
Our HyantX™ delivery system was designed to minimize the dosage required of a drug through enhanced targeted delivery, thereby limiting skin irritation associated with excess drug on the skin. Learn more from our CEO's latest presentation:
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 31. svi
BioPharmX is a specialty pharmaceutical company focused on developing products that treat chronic dermatologic conditions that are not being adequately addressed or those where current therapies and approaches are suboptimal
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 30. svi
is a chronic dermatologic condition characterized by redness, stinging & inflammatory lesions primarily on the face. Learn more about our Ph 2b trial of BPX-04 which we anticipate reporting topline efficacy & safety results in July 2019
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 28. svi
We've completed patient visits in our Phase 2b trial of BPX-04 for , a chronic dermatologic condition characterized by redness, stinging and inflammatory lesions primarily on the face
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 23. svi
BPX-04 is a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular that leverages our HyantX™ topical delivery system. We recently announced our last patient visit in a Phase 2b trial:
Reply Retweet Označi sa "sviđa mi se"
BioPharmX 23. svi
"We are pleased to announce this important milestone and look forward to reporting topline results from the study in early July 2019, subject to successful database lock and results validation," said BioPharmX CEO
Reply Retweet Označi sa "sviđa mi se"